Compare Ginkgo Bioworks Holdings Inc (DNA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Charles Schwab Corporation Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Charles Schwab Corporation Common Stock trades at $101.41 (market cap $175.83B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 297.7× Ginkgo Bioworks Holdings Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.27% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SCHW | |
|---|---|---|
Market Cap | $590.53M | $175.83B |
Sector | Health | Financials |
52-Week High | $16.14 | $107.21 |
52-Week Low | $5.48 | $85.35 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Charles Schwab (SCHW) trades at $102.38, down 0.72% on the day, with a bullish technical outlook and strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.43 versus $1.40 expected, highlight robust profitability. The stock is supported by a 21.79% ROE and a net income margin of 37.99%, with revenue growth to $23.92 billion in 2025. Positive sentiment is fueled by a Zacks Strong Buy upgrade and a consensus price target of $122.71, suggesting 20% upside.
Outlook remains favorable given earnings momentum and retail trading growth, but risks include interest rate sensitivity and competitive pressures. Analyst consensus is 58% buy, with institutional confidence bolstered by a recent dividend payment. The stock's valuation at a P/E of 20.35 appears reasonable relative to growth, though high RSI levels indicate potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
